Andexanet Alfa 与四因子凝血酶原复合物逆转因子 Xa 抑制剂相关颅内出血的比较
本研究为单中心回顾性队列,纳入 44 例口服因子 Xa 抑制剂相关颅内出血(16 例创伤性、28 例自发性)的成人患者,其中 28 例接受 Andexanet Alfa、16 例接受四因子凝血酶原复合物。主要终点为给药后 6 h 和 24 h 头颅 CT 出血稳定性,两组无差异(6 h:78% vs 71%,p=0.71;24 h:88% vs 60%,p=0.15)。自发性脑实质出血亚组的血肿体积变化、出院时 mRS<3 的良好功能结局(36% vs 38%,校正 p=0.81)及住院期间血栓事件(7% vs 0,p=0.53)均无差异。作者指出样本量小、可能把握度不足,需多中心协作进一步研究。
要点
- 单中心回顾性研究纳入 44 例 FXi 相关 ICH 成人患者,AA 组 28 例、4F-PCC 组 16 例,中位年龄 79 岁。
- 主要终点头颅 CT 出血稳定性在 6 h(78% vs 71%,p=0.71)和 24 h(88% vs 60%,p=0.15)两组均无差异。
- 出院时 mRS<3 的良好功能结局两组相似(36% vs 38%,校正 p=0.81),住院期间血栓事件亦无差异(7% vs 0,p=0.53)。
- 作者明确认为该分析可能把握度不足,不能据此判定两种逆转策略等效,需多中心协作网络进一步验证。
适用人群与场景
- 口服因子 Xa 抑制剂相关颅内出血的成人患者,包括创伤性和自发性颅内出血。
- 原文为单中心回顾性连续病例,中位年龄 79 岁(范围 72-86),女性占 36%。
- 自发性颅内出血中多数为脑实质出血(19 例,68%)。
诊断标准与关键阈值
- FXi 相关 ICH:口服因子 Xa 抑制剂相关的创伤性或自发性颅内出血。
- 主要终点 ICH 稳定性:定义为从 ICH 起病时初始头颅 CT 到 AA 或 4F-PCC 给药后 6 h 和 24 h 复查 CT 的血量相似。
- 自发性脑实质出血亚组在逆转后 6 h 和 24 h 测量血肿体积。
- 良好功能结局:出院时改良 Rankin 评分(mRS)小于 3。
处置流程与药物剂量
- 原文未提及 AA 的具体剂量、给药途径、频次或目标值。
- 原文未提及 4F-PCC 的具体剂量、给药途径、频次或目标值。
- 原文仅描述患者接受 AA 或 4F-PCC 逆转治疗,并在给药后 6 h 和 24 h 复查头颅 CT 评估出血稳定性。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或需要立刻处理的情况。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究,共 44 例患者(16 例创伤性、28 例自发性 ICH)。
- 干预与对照:28 例(64%)接受 Andexanet Alfa,16 例(36%)接受四因子凝血酶原复合物。
- 主要终点:6 h CT 稳定性 AA 组 21 例(78%)vs 4F-PCC 组 10 例(71%),p=0.71;24 h 分别为 15 例(88%)vs 6 例(60%),p=0.15。
- 出院时 mRS<3:AA 组 10 例(36%)vs 4F-PCC 组 6 例(38%),校正 p=0.81。
- 住院期间血栓栓塞事件:AA 组 2 例(7%)vs 4F-PCC 组 0 例,p=0.53。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究(原文标注为 retrospective review)。
- 局限:样本量有限(44 例),作者指出分析可能把握度不足(underpowered),需多中心协作网络进一步研究;回顾性设计、单中心、两组样本量不均衡(28 vs 16)。
对床旁实践的改变
- 在 FXi 相关 ICH 患者中,现有有限数据未显示 AA 与 4F-PCC 在影像稳定、出院功能结局或血栓事件上的差异,不能据此认为两者等效。
- 由于研究把握度不足,床旁选择 AA 或 4F-PCC 时不应以本研究结果作为唯一依据,需结合其他证据与患者具体情况。
- 原文未提供剂量方案,不能将本研究中的用药方案直接转化为通用推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: There are limited data on the risks and benefits of using andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F-PCC) to reverse factor Xa inhibitors (FXi) associated intracranial hemorrhage (ICH). We sought to describe our experience with AA or 4F-PCC in patients with oral FXi-related traumatic and spontaneous ICH.
METHODS: We conducted a retrospective review of consecutive adult patients with FXi-related ICH who received AA or 4F-PCC. FXi-related ICH cases included traumatic and spontaneous intracranial hemorrhages. Our primary analysis evaluated ICH stability on head computed tomography scan (CT), defined as a similar amount of blood from the initial scan at the onset of ICH to subsequent scans, at 6-h and 24-h post-administration of AA or 4F-PCC. For the subset of spontaneous intraparenchymal hemorrhages, volume was measured at 6-h and 24-h post-reversal. In secondary analyses, we evaluated good functional outcome at discharge, defined as a Modified Rankin Score of less than 3, and the incidence of thrombotic events after AA or 4F-PCC adminstration, during hospitalization.
RESULTS: A total of 44 patients (16 traumatic and 28 spontaneous ICH) with median age of 79 years [72-86], 36% females, with a FXi-related ICH, were included in this study. The majority of spontaneous ICHs were intraparenchymal 19 (68%). Twenty-eight patients (64%) received AA and 16 patients (36%) received 4F-PCC. There was no difference between AA and 4F-PCC in terms of CT stability at 6 h (21 [78%] vs 10 [71%], p = 0.71) and 24 h (15 [88%] vs 6 [60%], p = 0.15). In a subgroup of patients with spontaneous intraparenchymal hemorrhage, there was no difference in the degree of achieved hemostasis based on hematoma volume between AA and 4F-PCC at 6 h (9.3 mL [6.9-26.4] vs 10 mL [9.4-22.1], adjusted p = 0. 997) and 24-h (9.2 mL [6.1-18.8] vs 9.9 [9.4-21.1], adjusted p = 1). The number of patients with good outcome based on mRS on discharge were 10 (36%) and 6 (38%) in the AA and 4F-PCC groups, respectively (adjusted p = 0.81). The incidence of thromboembolic events was similar in the AA and 4F-PCC groups (2 [7%] vs 0, p = 0.53).
CONCLUSION: In this limited sample of patients, we found no difference in neuroimaging stability, functional outcome and thrombotic events when comparing AA and 4F-PCC in patients with FXi-related ICH. Since our analysis is likely underpowered, a multi-center collaborative network devoted to this question is warranted.
参考来源
- Ammar AA, Ammar MA, Owusu KA, et al. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Neurocrit Care. 2021. PMID: 33403588. doi:10.1007/s12028-020-01161-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。